Price
$0.1895
Decreased by -2.87%
Dollar Volume (20D)
60.28 K
ADR%
10.41
Earnings Report Date (estimate)
Mar 29, 24
Shares Float
6.25 M
Shares Outstanding
10.16 M
Shares Short
443.29 K
Market Cap.
1.98 M
Beta
0.51
Price / Earnings
N/A
20D Range
0.18 0.25
50D Range
0.15 0.31
200D Range
0.15 1.47
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -1.29
Increased by +7.79%
-
Aug 15, 23 -0.7
Decreased by -139.08%
-
May 15, 23 -1.27
Decreased by -227.09%
-
Mar 31, 23 -10.89
Decreased by -1.19 K%
-0.11
Decreased by -9.8 K%
Nov 10, 22 -1.4
Increased by +36.36%
0.2
Decreased by -800%
Aug 9, 22 1.8
Increased by +1.16 K%
-2.6
Increased by +169.23%
May 16, 22 1
Increased by +233.33%
-2.6
Increased by +138.46%
Mar 31, 22 1
Increased by +272.56%
-2.6
Increased by +138.46%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-10.27 M
Increased by +73.62%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-3.68 M
Decreased by -135.38%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-4.73 M
Decreased by -169.5%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
-21.74 M
Decreased by -2.2 K%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-38.92 M
Decreased by -312.71%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
10.4 M
Increased by +652.94%
Increased by +N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
6.81 M
Increased by +142.03%
Increased by +N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
1.04 M
Increased by +287.54%
Increased by +N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.